Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Osteoporosis
•
Primary Care
Would you use anabolic agents (romosozumab or PTH analogues) for osteoporosis treatment in patients with CKD?
Related Questions
Do you recommend adjusting the duration of a drug holiday based on the specific bisphosphonate used when treating osteoporosis?
Are SGLT2 inhibitors contraindicated in patients with osteoporosis and history of vertebral and hip fractures?
When do you recommend using trabecular bone score (TBS) for managing osteoporosis?
Would you order a repeat DEXA scan 1 year later for a kidney transplant patient who had an initial DEXA scan within the first 6 months post-transplant showing osteopenia but no history of fractures, and who has been stable on glucocorticoid-free immunosuppressive therapy?
Would you continue Forteo treatment past the recommended 2 years if T scores remain low and procollagen (P1NP) is elevated and if so, how would you monitor response?
Would you continue zolendronic acid infusions if the bone density decreases significantly in year two?
Would you consider using Evenity in an elderly patient with rate controlled atrial fibrillation without history of MI or CVA?
How do you determine osteoporosis treatment response when patients have discrepant DEXA scan results during monitoring (eg improved BMD of the hip and spine but worsening BMD of the femoral neck)?
Do you routinely use anti-resorptive medications in patients who have osteoporosis and longstanding hypoparathyroidism?
Would you have concerns about combining romosuzumab and IVIG in a patient with dermatomyositis and osteoporosis?
